Corbus releases topline results for the phase 3 study of lenabasum in dermatomyositis. While it didn't meet the primary...
Tag Archive for: myositis research
Register & Submit Questions: Myositis, Immunosuppressants, and COVID Vaccine Response. A panel of John Hopkins physician researchers will be...
Episode 1: Communicating with your doctor as a myositis patient

Watch the recording of Episode 1 of our new webinar series, Managing Your Care Starts with You, together with...
Clinical trials are a key research tool for advancing medical knowledge and patient care. Join Kezar Life Sciences as...
AllStripes provides an update on the inclusion body myositis (IBM) research program and the video includes a step-by-step walkthrough...
Join MSU in our continued and exciting partnership with AllStripes, formerly RDMD, with a live video IBM research update...
After Diagnosis: The Burden of Care and the Evolving Doctor/Patient Relationship

Dr. Salman Bhai joins MSU to share best practices related to myositis care and empowers you to seek the...
Myositis Patients and Families Come First: Introducing Dr. Salman Bhai

Meet Dr. Bhai who is working together with MSU, collaborating on myositis patient-centered research, patient education, grants, and improving...
Manuel Lubinus, MBA, Ph.D. has been appointed to our newly created Scientific Advisory Board as Patient-Centric Research Advisor and...
Help researchers and clinicians better understand how patients with myositis and other autoimmune conditions feel about COVID-19/the novel coronavirus.
Introduction to the PRESIDIO Clinical Trial of KZR-616 for the Treatment of Polymyositis and Dermatomyositis

Dr. Mary Katherine (MK) Farmer, MD, Rheumatologist and Senior Medical Director at Kezar Life Sciences, joined us live online...
Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis

Orphazyme's Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis, an incurable rare progressively debilitating muscle-wasting disease...
Introduction to Ra Pharma & the Potential of Zilucoplan for the Treatment of IMNM Webinar

Ben Matys, Sr. Clinical Trial Manager, and Ramin Farzaneh-Far, Chief Medical Officer of Ra Pharma, joined MSU) on November...
Myositis Support and Understanding (MSU) partners with the University of Pittsburgh for a new NIH-sponsored study entitled, “Myositis Patient...
Join the Yale Inclusion Body Myositis Registry

The success of the Registry effort depends on the cooperative efforts of IBM patients around the world. The IBM...
Watch the AllStripes, formerly RDMD, video session we did in 2020 to learn more about the Inclusion Body Myositis...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for Sporadic Inclusion Body Myositis Video

The ongoing Arimoclomol Clinical Trial for sIBM continues to generate a lot of questions from our community. As part...
The Performance of the EULAR/ACR IIM classification criteria in an expert-defined 10 year incident cohort

This paper assesses the performance of EULAR/ACR classification criteria in a cohort of IIM cases and examines how subtypes...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for sIBM

Watch "An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for sIBM" with Dr. Mazen Dimachkie,...